Key Developments: TherapeuticsMD Inc (TXMD.A)
2.59USD
4:00pm EDT
$-0.03 (-1.14%)
$2.62
$2.61
$2.71
$2.58
37,483
--
$3.23
$2.03
Latest Key Developments (Source: Significant Developments)
TherapeuticsMD Inc Announces Trading of Common Stock On NYSE MKT Under Symbol TXMD
TherapeuticsMD Inc announced that its common stock has been approved for listing on the NYSE MKT, the premier U.S. equities market for listing and trading of small growth companies. Trading is expected to commence on the NYSE MKT on April 23, 2013, under the ticker symbol “TXMD”. Full Article
TherapeuticsMD Inc Announces Pricing Of Public Offering Of Common Stock
TherapeuticsMD Inc announced the pricing of previously announced underwritten public offering of 29,411,765 shares of common stock, offered at a price of $1.70 per share to the public. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $50.0 million, before deducting underwriting discounts, commissions, and other estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about March 20, 2013. TherapeuticsMD has granted the underwriters a 30-day option to purchase up to an aggregate of 4,411,765 additional shares of common stock to cover over-allotments, if any. Jefferies LLC acted as sole book-running manager for the offering, and Noble Financial Capital Markets acted as co-manager. Full Article
TherapeuticsMD Inc Announces $50,000,000 Proposed Public Offering of Common Stock
TherapeuticsMD Inc announced that it intends to offer and sell, subject to market and other conditions, $50,000,000 of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC is acting as sole book-running manager for the offering, and Noble Financial Capital Markets is acting as co-manager for the offering. Full Article
TherapeuticsMD Inc Announces $8.5 Million Private Placement
TherapeuticsMD Inc announced that it entered into a definitive Securities Purchase Agreement with accredited investors covering an aggregate of 3,953,489 shares of the Company’s common stock in a private placement at a purchase price of $2.15 per share, which will result in aggregate gross proceeds to the Company of approximately $8.5 million. The Company intends to use the funds from the private placement to fund the pharmacokinetic trials required before it can begin Phase III trials on its three investigational new drugs (INDs) that were submitted to the U.S. Food and Drug Administration (FDA). These drug development candidates are for menopause symptom relief, and two of the three submitted INDs have been accepted by the FDA. The accepted INDs are for a progestin product and an estrogen product, while the third drug will be a product that is a combination of progestin and estrogen. The Company’s strategy is to begin its Phase III trials as early as the first quarter of 2013. Full Article
AMHN, Inc. Announces Name Change To TherapeuticsMD, Inc; Acquires VitaMedMD, LLC
AMHN, Inc. announced that it changed its name to TherapeuticsMD, Inc. in July in anticipation of acquiring VitaMedMD, LLC. On October 4, 2011, the Company closed the transaction in which it acquired 100% of the outstanding ownership of VitaMedMD in exchange for the issuance of Company securities equating to an aggregate of approximately 70,000,000 shares of the Company's Common Stock. The issued securities are covered by a lock-up agreement which, among other things, restricts the sale of the securities for a period of eighteen (18) months. As a result of the acquisition, VitaMedMD is now a wholly owned subsidiary of the Company. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
